Side-by-side · Research reference

IGF-DESvsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED8/60 cited

BHuman-MechanisticAUTO-DRAFTED11/40 cited

IGF-DES

IGF-1 Analogue · Truncated N-Terminal

~10×Potency vs IGF-1

ReducedIGFBP binding

ResearchStatus

Injection (local or systemic) · Research protocols onlyBredehöft 2008

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter

IGF-DES

Selank

Primary target

IGF-1 receptor (IGF1R)Shields 2007

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Pathway

IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Downstream effect

Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Feedback intact?

Unknown — no human endocrine feedback data

No GABA-receptor binding; no dependence reportedMedvedev 2007

Origin

Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Antibody development

—

02Dosage Protocols

Parameter

IGF-DES

Selank

Research dose range

10–100 ng/mL (in vitro); μg doses (animal models)

Highly context-dependent; no standardized human protocol.

—

Route

Subcutaneous or intramuscular (local injection favored)

Local delivery maximizes tissue-specific uptake.

—

Frequency

Variable — daily to multiple times daily in research

2–3× per day during stress

Evidence basis

Animal models + in vitro only

Human-mechanistic + Russian clinical trialsMedvedev 2007

Human data

None — no clinical trials

—

Half-life

Shorter than IGF-1 due to reduced IGFBP binding

Rapid tissue uptake, limited systemic circulation.

Short (minutes plasma); CNS effect lasts ~3 hr

Standard dose

—

150–300 mcg / dose intranasalZaderej 2014

Lower / starter dose

—

75 mcg / dose

Duration

—

10–14 day cycles, repeated as needed

Reconstitution

—

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

—

Morning + early afternoon preferred

03Metabolic / Fat Loss Evidence

Parameter

IGF-DES

Selank

Primary mechanism

Indirect via muscle hypertrophy → metabolic rate elevation

—

Direct lipolysis

Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic

—

Prostate model

Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002

Context-specific anti-proliferative effect, not fat loss.

—

04Side Effects & Safety

Parameter

IGF-DES

Selank

Hypoglycemia risk

Theoretical — IGF-1 axis enhances glucose uptake

—

Mitogenic risk

Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002

—

Injection site reaction

Expected — erythema, irritation, local swelling

—

Edema / Fluid retention

Possible via sodium retention (IGF-1 axis effect)

—

Human safety data

Absent — no human trials, all effects theoretical or extrapolated

—

Unknown long-term effects

No chronic dosing studies in humans; endocrine, metabolic consequences unknown

—

Nasal irritation

—

Mild burning or congestion (transient)

Sedation

—

None — distinct from benzodiazepinesMedvedev 2007

Dependence / withdrawal

—

None reported in clinical useZaderej 2014

Cognitive impairment

—

None — opposite effect (enhancement)

Allergic reaction

—

Rare hypersensitivity

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

IGF-DES

·Active malignancy or history of cancer (mitogenic risk)
·Pregnancy / lactation (no safety data)
·Hypoglycemia disorders

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

IGF-DES

·Diabetes mellitus (unpredictable glucose effects)
·Renal or hepatic impairment (clearance unknown)
·Edema-prone conditions (heart failure, nephrotic syndrome)

Selank

·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter

IGF-DES

Selank

1. Research context only

Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Reconstitution (if lyophilized)

Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

3. Injection site

Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

4. Timing

Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.

Refrigerate after reconstitution; ≤30 days. Light-protected.

5. Needle gauge

27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.

Avoid co-administration with strong sedatives or other anxiolytics initially.

6. Monitoring

Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.

—

06Stack Synergy

IGF-DES

+ BPC-157

Moderate

View BPC-157 →

Des(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.

Des(1-3)IGF-1: Research dose post-workout (local IM)
BPC-157: 250–500 mcg SQ, daily or twice daily
Frequency: Daily or per research protocol
Primary benefit: Accelerated muscle repair, enhanced hypertrophy, connective tissue support

+ TB-500

Moderate

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.

Des(1-3)IGF-1: Research dose post-workout (local IM)
TB-500: 2–5 mg SQ, 2× weekly
Frequency: Per research cycle
Primary benefit: Muscle hypertrophy, injury recovery, vascular support

Selank

— no documented stacks